Scroll

irbesartan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
angiotensin II receptor antagonists, antihypertensive (non-peptidic)	1481	138402-11-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: irbesartan aprovel irbesartan hydrochloride karvea ifirmasta irbesartan HCl	A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease. Molecular weight: 428.54 Formula: C25H28N6O CLOGP: 4.69 LIPINSKI: 1 HAC: 7 HDO: 1 TPSA: 87.13 ALOGS: -4.70 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

irbesartan
aprovel
irbesartan hydrochloride
karvea
ifirmasta
irbesartan HCl

A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.

Molecular weight: 428.54
Formula: C25H28N6O
CLOGP: 4.69
LIPINSKI: 1
HAC: 7
HDO: 1
TPSA: 87.13
ALOGS: -4.70
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.15	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	70 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
EoM (Fraction excreted unchanged in urine)	2.50 %	Benet LZ, Broccatelli F, Oprea TI
CL (Clearance)	2.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	14 hours	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	10 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.94 L/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.10 %	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.08 mg/mL	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Aug. 26, 1997	EMA	SANOFI WINTHROP INDUSTRIE
Sept. 30, 1997	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	523.41	10.47	889	56550	262526	63169057
Neurologic neglect syndrome	352.87	10.47	121	57318	2600	63428983
Carotid artery thrombosis	349.73	10.47	121	57318	2673	63428910
Personality disorder	321.62	10.47	139	57300	5672	63425911
Adjustment disorder	308.51	10.47	114	57325	3064	63428519
Hyponatraemia	291.20	10.47	428	57011	111472	63320111
Hemiplegia	284.61	10.47	148	57291	9175	63422408
Affect lability	243.75	10.47	142	57297	11009	63420574
Sensory loss	212.28	10.47	126	57313	10112	63421471
Motor dysfunction	201.37	10.47	124	57315	10637	63420946

Showing 1 to 10 of 273 entries

Previous1 2 3 4 5…28Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	273.51	11.54	849	37955	304139	34613988
Hyperkalaemia	142.40	11.54	267	38537	69122	34849005
Lactic acidosis	114.96	11.54	166	38638	34606	34883521
Death	101.10	11.54	180	38624	397869	34520258
Hyponatraemia	73.31	11.54	230	38574	82461	34835666
Anorectal discomfort	64.35	11.54	35	38769	1929	34916198
Oesophageal pain	61.20	11.54	26	38778	823	34917304
Hypotension	57.11	11.54	431	38373	221218	34696909
Syncope	52.63	11.54	221	38583	91230	34826897
Failure to suspend medication	47.50	11.54	18	38786	420	34917707

Showing 1 to 10 of 172 entries

Previous1 2 3 4 5…18Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	708.47	10.14	1641	82916	517763	79142068
Hyponatraemia	336.75	10.14	644	83913	177204	79482627
Neurologic neglect syndrome	322.58	10.14	120	84437	2787	79657044
Hyperkalaemia	321.83	10.14	494	84063	113904	79545927
Carotid artery thrombosis	316.85	10.14	120	84437	2933	79656898
Personality disorder	283.82	10.14	136	84421	6010	79653821
Adjustment disorder	262.23	10.14	113	84444	3887	79655944
Hemiplegia	228.30	10.14	161	84396	14778	79645053
Lactic acidosis	226.78	10.14	324	84233	70035	79589796
Affect lability	216.70	10.14	140	84417	11119	79648712

Showing 1 to 10 of 362 entries

Previous1 2 3 4 5…37Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	C09CA04	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN Angiotensin II receptor blockers (ARBs), plain
ATC	C09DA04	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and diuretics
ATC	C09DB05	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and calcium channel blockers
ATC	C09DX07	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs), other combinations
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:61016	angiotensin receptor antagonists
CHEBI has role	CHEBI:78298	environmental contaminants
FDA EPC	N0000175561	Angiotensin 2 Receptor Blocker
FDA MoA	N0000000070	Angiotensin 2 Receptor Antagonists

Showing 1 to 10 of 14 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Diabetic renal disease	indication	127013003
Chronic heart failure	off-label use	48447003
Atrial fibrillation	off-label use	49436004	DOID:0060224
Diastolic heart failure	off-label use	418304008	DOID:9775
Nondiabetic Proteinuric Nephropathy	off-label use
Anuria	contraindication	2472002	DOID:2983
Hypercholesterolemia	contraindication	13644009
Hyperkalemia	contraindication	14140009
Secondary angle-closure glaucoma	contraindication	21571006

Showing 1 to 10 of 33 entries

Previous1 2 3 4Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.37	acidic
pKa2	3.63	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Type-1 angiotensin II receptor	GPCR	P30556	AGTR1_HUMAN	ANTAGONIST	Ki	9.10	CHEMBL	CHEMBL
Endothelin-1 receptor	GPCR	P25101	EDNRA_HUMAN		Ki	5	CHEMBL
Sodium/bile acid cotransporter	Transporter	Q14973	NTCP_HUMAN	INHIBITOR	Ki	4.92	IUPHAR
Type-1B angiotensin II receptor	GPCR		AGTRB_RAT		Ki	9.10	CHEMBL
Angiotensin II receptor (AT-1) type-1	GPCR		AGTRA_RAT AGTRB_RAT		IC50	8.89	CHEMBL
Angiotensin II receptor	GPCR		AGTRA_RAT AGTRB_RAT AGTR2_RAT		IC50	8.89	CHEMBL

Showing 1 to 6 of 6 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
006921	NDDF
108585000	SNOMEDCT_US
329055-23-4	SECONDARY_CAS_RN
3749	PUBCHEM_CID
386877005	SNOMEDCT_US
4021071	VUID
4021071	VANDF
4917	MMSL
52343	MMSL
589	IUPHAR_LIGAND_ID

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Avalide	HUMAN PRESCRIPTION DRUG LABEL	2	0024-5855	TABLET, FILM COATED	150 mg	ORAL	NDA	30 sections
Avalide	HUMAN PRESCRIPTION DRUG LABEL	2	0024-5855	TABLET, FILM COATED	150 mg	ORAL	NDA	30 sections
Avalide	HUMAN PRESCRIPTION DRUG LABEL	2	0024-5856	TABLET, FILM COATED	300 mg	ORAL	NDA	30 sections
Avalide	HUMAN PRESCRIPTION DRUG LABEL	2	0024-5856	TABLET, FILM COATED	300 mg	ORAL	NDA	30 sections
Avapro	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5850	TABLET, FILM COATED	75 mg	ORAL	NDA	29 sections
Avapro	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5851	TABLET, FILM COATED	150 mg	ORAL	NDA	29 sections
Avapro	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5852	TABLET, FILM COATED	300 mg	ORAL	NDA	29 sections
Irbesartan	HUMAN PRESCRIPTION DRUG LABEL	1	0955-1040	TABLET, FILM COATED	75 mg	ORAL	NDA AUTHORIZED GENERIC	27 sections
Irbesartan	HUMAN PRESCRIPTION DRUG LABEL	1	0955-1041	TABLET, FILM COATED	150 mg	ORAL	NDA AUTHORIZED GENERIC	27 sections
Irbesartan	HUMAN PRESCRIPTION DRUG LABEL	1	0955-1042	TABLET, FILM COATED	300 mg	ORAL	NDA AUTHORIZED GENERIC	27 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next